Katherine E Mues

TL;DR: A summary of Medicare data is provided, including the types of data that are captured, and how they may be used in epidemiologic and health outcomes research, to highlight strengths, limitations, and key considerations when designing a study using Medicare data.

TL;DR: Persistence with and adherence to statin therapy remain low, particularly among those without CHD, and statin adherence was lower among younger, black, and Hispanic patients versus white patients and those initiating a high‐intensity statin dosage.

TL;DR: Examination of contemporary use of medications to reduce cardiovascular risk in a large cohort of US patients with diabetes and ASCVD found no evidence of suboptimal use of evidence-based therapies.

TL;DR: The GOULD study as discussed by the authors tracked LDL-C treatment patterns in the US over 2 years and found that only 17% of patients with LDL-c levels less than 70 mg/dL at 2 years had two-thirds of the patients achieving the optimal level at the end of 2 years.

TL;DR: Despite having high risk for ASCVD events, patients with PAD were less likely to be taking a statin versus those with CHD or cerebrovascular disease, and ASCVD risk-reduction interventions including statin therapy in patientswith PAD are warranted.